Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Fig. 4

Proportion of responders at 3 months, stratified by certolizumab level (mg/L). a ASDAS CII responders in axial spondyloarthritis. b EULAR good/moderate response in rheumatoid arthritis. c DAS28 improvement ≥ 0.6 in psoriatic arthritis. ASDAS CII, Clinically important improvement the Ankylosing Spondylitis Disease Activity Score; EULAR good/moderate, European League Against Rheumatism good/moderate response; DAS28 improvement ≥ 0.6, improvement of ≥ 0.6 in 28-joint Disease Activity Score

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us